120 related articles for article (PubMed ID: 15885576)
41. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
42. [The assessment of pathological PSA values by the general practitioner--observation or intervention?].
Braun KP; Brookman-Amissah S; May M; Grassmel Y; Hoschke B; Braun V
Aktuelle Urol; 2009 May; 40(3):171-4. PubMed ID: 19479670
[TBL] [Abstract][Full Text] [Related]
43. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
44. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
45. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy.
Cohen JK; Miller RJ; Ahmed S; Lotz MJ; Baust J
Urology; 2008 Mar; 71(3):515-8. PubMed ID: 18342200
[TBL] [Abstract][Full Text] [Related]
46. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
47. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of PSA nadir < or =4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer.
Nickers P; Albert A; Waltregny D; Deneufbourg JM
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):73-7. PubMed ID: 16503381
[TBL] [Abstract][Full Text] [Related]
49. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
50. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
51. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
52. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
53. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI
BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305
[TBL] [Abstract][Full Text] [Related]
54. Is there a role for serum human tissue kallikrein in detection of prostate cancer?
Ochiai A; Shukla A; Davis JW; Fritsche HA; Bhadkamkar V; Babaian RJ
Urology; 2007 Sep; 70(3):519-22. PubMed ID: 17905108
[TBL] [Abstract][Full Text] [Related]
55. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
[TBL] [Abstract][Full Text] [Related]
56. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
[TBL] [Abstract][Full Text] [Related]
57. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
Blana A; Brown SC; Chaussy C; Conti GN; Eastham JA; Ganzer R; Murat FJ; Pasticier G; Rebillard X; Rewcastle JC; Robertson CN; Thuroff S; Ward JF
BJU Int; 2009 Oct; 104(8):1058-62. PubMed ID: 19388986
[TBL] [Abstract][Full Text] [Related]
58. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer.
Dvorak T; Chen MH; Renshaw AA; Loffredo M; Richie JP; D'Amico AV
Urology; 2005 Nov; 66(5):1024-8. PubMed ID: 16286117
[TBL] [Abstract][Full Text] [Related]
59. Prostate cryoablation: prospective analysis comparing high- and low-risk prostate cancer outcomes.
El Hayek OR; Alfer W; Reggio E; Pompeo AC; Arap S; Lucon AM; Srougi M
Urol Int; 2008; 81(2):186-90. PubMed ID: 18758217
[TBL] [Abstract][Full Text] [Related]
60. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
Akyol F; Ozyigit G; Selek U; Karabulut E
Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
